CA-FORESCOUT
24.1.2024 07:02:27 CET | Business Wire | Press release
In the last year, the world’s critical infrastructure – the medical, power, communications, waste, manufacturing, and transportation equipment that connects people and machines – has been under near-constant attack. Forescout Research – Vedere Labs recorded more than 420 million attacks between January and December 2023. That is 13 attacks per second, a 30% increase from 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240123671589/en/
2023 Global Threat Roundup Highlights from Forescout Research (Graphic: Business Wire)
Forescout, a global cybersecurity leader, unveiled the global findings of recorded attacks in its Adversary Engagement Environment (AEE) in the new report, “2023 Global Threat Roundup.” The AEE is maintained by Vedere Labs, a leading global team dedicated to uncovering vulnerabilities in and threats to critical infrastructure.
Despite the formidable challenges posed by the ongoing surge in cyber-activity, there is an optimistic path forward. Elisa Costante, VP of Research at Forescout Research – Vedere Labs, highlights the potential for positive change, stating, "While it's true that current efforts have fallen short in fully harnessing crucial technology to fortify critical assets and assess risks, there is an opportunity for improvement."
Read the blog: 2023 Global Threat Roundup: Trends in Cyberattacks, Exploits and Malware
Here are the top five insights from Forescout Research:
-
Not Yet Dormant: Log4j Dampens Software Library Exploits
Exploits against software libraries are witnessing a decline due to the waning popularity of Log4j exploits. This lull has given rise to a surge in exploits targeting network infrastructure and Internet of Things (IoT) devices.
Among the IoT landscape, the spotlight falls on IP cameras, building automation systems, and network-attached storage, emerging as the most sought-after targets for malicious actors.
Only 35% of exploited vulnerabilities made an appearance in the Cybersecurity and Infrastructure Security Agency's (CISA) Known Exploited Vulnerabilities (KEV) list. This divergence emphasizes the need for a proactive and comprehensive approach to cybersecurity, transcending reliance on known vulnerability databases.
-
OT Protocols Bear the Brunt
Operational Technology (OT) finds itself under relentless assault, with five key protocols bearing the brunt of persistent attacks. The primary targets include protocols used in industrial automation and power sectors, such as Modbus, subject to a staggering one-third of all attacks, closely followed by Ethernet/IP, Step7, and DNP3, each accounting for approximately 18% of the onslaught. IEC10X rounds out this list with 10% of attacks, leaving the remaining 2% distributed among various protocols, with BACnet emerging as the majority.
Building automation protocols, such as BACnet, experience less frequent scans. However, the relative scarcity of scans belies an alarming trend—targeted exploits against vulnerabilities in building automation devices are more prevalent.
-
Post-Exploitation Tactics Shift
Persistence tactics mark a 50% surge from 3% in 2022, along with discovery (roughly 25%) and execution (the other roughly 25%). While most observed commands used by threat actors remain targeted at generic Linux systems, a notable trend involves specific commands executed for network operating systems found on widely used routers.
-
Malware Families Remain Strong
Malware families persist as formidable threats. The Agent Tesla Remote Access Trojan (RAT) commands a significant 16% share of observed malicious activity. Following closely are variants of the Mirai botnet, comprising 15%, and the Redline info stealer, holding its ground at 10%.
Among command-and-control servers, Cobalt Strike emerges as the undisputed leader, commanding a substantial 46% share, trailed by Metasploit at 16%, and the emerging Sliver C2 at 13%. Most of these servers are in the United States, constituting 40% of the global landscape, with China and Russia following at 10% and 8%, respectively.
-
Threats Unleashed Across 163 Countries
Threat actors have cast a digital net far and wide, impacting 163 countries. The United States stands as the primary target, bearing the brunt with 168 malicious actors setting their sights on the nation. Other countries include the United Kingdom (88), Germany (77), India (72), and Japan (66).
The usual suspects boast high concentrations of threat actors: China (155), Russia (88), and Iran (45), collectively representing nearly half of all identified threat groups. The crosshairs of these malicious entities are predominantly fixed on three key sectors: Government, Financial Services, and Media and Entertainment. As the primary pillars of societal infrastructure, these industries are at the forefront of cyber warfare, emphasizing the need for heightened security measures and collaborative efforts.
Costante continues, “The key lies in achieving comprehensive visibility, ensuring real-time contextual awareness of every device, whether managed or unmanaged. By doing so, large enterprises can transition from a reactive defense posture to a more proactive approach, steering clear of the futile game of security whack-a-mole. This shift towards enhanced visibility and proactive defense strategies signals a brighter outlook for critical infrastructure.”
For more information, download the full report, “2023 Global Threat Roundup,” now at https://www.forescout.com/resources/research-report_2023-threat-roundup.
How Forescout Research Works
Forescout Research employs its Adversary Engagement Environment (AEE) to conduct analysis, leveraging a blend of real and simulated connected devices. This dynamic environment functions as a robust tool, enabling the pinpointing of incidents and the identification of intricate threat actor patterns at a granular level. The overarching objective is to elevate responses to complex critical infrastructure attacks by leveraging the detailed insights and understanding derived from this specialized deception environment. The AEE is maintained by Vedere Labs, a leading global team dedicated to uncovering vulnerabilities in and threats to critical infrastructure. Forescout products directly leverage this research, which is also shared openly with vendors, agencies, and other researchers.
About Forescout
Forescout Technologies, Inc., a global cybersecurity leader, continuously identifies, protects and helps ensure the compliance of all managed and unmanaged connected cyber assets – IT, IoT, IoMT and OT. For more than 20 years, Fortune 100 organizations and government agencies have trusted Forescout to provide vendor-agnostic, automated cybersecurity at scale. The Forescout® Platform delivers comprehensive capabilities for network security, risk and exposure management, and extended detection and response. With seamless context sharing and workflow orchestration via ecosystem partners, it enables customers to more effectively manage cyber risk and mitigate threats.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240123671589/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
